Please assess the completion status of the following clinical trial:

Trial Title: A Gene Therapy Study for Hemophilia B

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent and comply with requirements of the study~* Males ≥18 y.o. with confirmed diagnosis of hemophilia B (≤2 IU/dL or ≤2% endogenous factor IX)~* Received ≥50 exposure days to factor IX products~* A minimum average of 4 bleeding events per year requiring episodic treatment of factor IX infusions or prophylactic factor IX infusions~* No measurable factor IX inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor IX protein~* Agree to use reliable barrier contraception until 3 consecutive samples are negative for vector sequences~Exclusion Criteria:~* Evidence of active hepatitis B or C~* Currently on antiviral therapy for hepatitis B or C~* Have significant underlying liver disease~* Have serological evidence\* of HIV-1 or HIV-2 with CD4 counts ≤200/mm3 (\* subjects who are HIV+ and stable with CD4 count \>200/mm3 and undetectable viral load are eligible to enroll)~* Neutralizing antibodies reactive with AAV-Spark100 above and/or below a defined titre~* Participated in a gene transfer trial within the last 52 weeks or in a clinical trial with an investigational drug within the last 12 weeks~* Unable or unwilling to comply with study assessments

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SPK-9001 (Type: EXPERIMENTAL): Single intravenous (i.v.) infusion of SPK-9001 \[an adeno-associated viral (AAV) vector with human factor IX gene\] Intervention: Gene Therapy / Gene Transfer

Based on this trial design, predict the completion outcome and termination type (if applicable).